Pfizer 2008 Annual Report Download - page 25

Financial Review
Pfizer Inc and Subsidiary Companies
regarding suicidal thoughts and behavior. We are working closely with the FDA to update the labeling for these products and we
hope that the labeling change will further facilitate important dialogue between patients and their doctors when considering
treatment options.
•Geodon/Zeldox, a psychotropic agent, is a dopamine and serotonin receptor antagonist indicated for the treatment of schizophrenia
and acute manic or mixed episodes associated with bipolar disorder. It is available in both an oral capsule and rapid-acting
intramuscular formulation. In 2008, Geodon worldwide revenues grew 18%, compared to 2007. Geodon is supported by Pfizer's
recently launched psychiatric field force and Geodon's efficacy and favorable tolerability and metabolic profiles.
•Celebrex, a treatment for the signs and symptoms of osteoarthritis and rheumatoid arthritis and acute pain in adults, experienced a 9%
increase in worldwide revenues to $2.5 billion in 2008, supported by continued educational and promotional efforts highlighting
Celebrex’s efficacy and safety profile.
See Notes to Consolidated Financial Statements—Note 19. Legal Proceedings and Contingencies for a discussion of recent
developments with respect to certain patent and product litigation relating to Celebrex.
•Zyvox is the world’s best-selling branded agent for the treatment of certain serious Gram-positive pathogens, including Methicillin-
Resistant Staphylococcus-Aureus (MRSA). MRSA remains a serious and growing threat in hospitals and the community. Zyvox is an
excellent first-line choice for the treatment of adults and children with complicated skin and skin structure infections and nosocomial
pneumonia due to known or suspected MRSA. Zyvox is the only FDA approved agent for MRSA that offers intravenous and oral
formulations for these indications. Its unique mechanism of action minimizes the potential for cross-resistance. To date, more than three
million patients have been treated worldwide. Zyvox worldwide sales grew 18% to $1.1 billion in 2008.
•Selzentry/Celsentri (maraviroc tablets), a CCR5 antagonist, is the first in a new class of oral HIV medicines in more than a decade
known as CCR5 antagonists. CCR5 antagonists work by blocking the CCR5 co-receptor, the virus’ predominant entry route into T-cells.
Selzentry/Celsentri stops the R5 virus on the outside surface of the cells before it enters, rather than fighting the virus inside, as do all
other classes of oral HIV medicines. Selzentry/Celsentri was approved in the U.S. and in Europe in 2007 and in Japan in 2008, and is
indicated for combination anti-retroviral treatment of treatment-experienced adults infected with only CCR5-tropic HIV-1, who have
evidence of viral replication and have HIV-1 strains resistant to multiple anti-retroviral agents. A diagnostic test confirms whether a
patient is infected with CCR5-tropic HIV-1, which is also known as “R5-virus.” We accelerated the Selzentry/Celsentri development
program to make it available to patients in need. Performance has been driven by increased access and reimbursement of tropism
testing, targeted promotion and combination therapy with new agents.
•Viagra remains the leading treatment for erectile dysfunction and one of the world’s most recognized pharmaceutical brands after more
than a decade. Viagra worldwide revenues grew 10% in 2008, compared to 2007.
See Notes to Consolidated Financial Statements—Note 19. Legal Proceedings and Contingencies for a discussion of recent
developments with respect to certain product litigation relating to Viagra.
•Detrol/Detrol LA, a muscarinic receptor antagonist, is the most prescribed branded medicine worldwide for overactive bladder. Detrol
LA is an extended-release formulation taken once a day. Detrol/Detrol LA worldwide revenues grew 2% to $1.2 billion in 2008,
compared to 2007.
See Notes to Consolidated Financial Statements—Note 19. Legal Proceedings and Contingencies for a discussion of recent
developments with respect to certain patent litigation relating to Detrol/Detrol LA.
•Sutent, for the treatment of advanced renal cell carcinoma, including metastatic renal cell carcinoma, and gastrointestinal stromal
tumors (GIST) after disease progression on, or intolerance to, imatinib mesylate, was launched in the U.S. in January 2006. It has now
been launched in all major markets, including Japan, where it was approved in April 2008 for the treatment of GIST, after failure of
imatinib treatment due to resistance, and for renal cell carcinoma not indicated for curative resection and mRCC. Sutent recorded
worldwide revenues of $847 million in 2008, an increase of 46% compared to 2007. We continue to drive growth in the U.S. and
internationally, supported by cost-effectiveness data and efficacy data in first-line mRCC—including 2-year survival data, which
represents the first time overall survival of two years has been seen in the treatment of advanced kidney cancer, as well as through
strong promotional efforts and the promotion of access and health care coverage. As of September 30, 2008, Sutent was the best-
selling medicine in the world for the treatment of first-line mRCC.
•Camptosar, indicated as first-line therapy for metastatic colorectal cancer in combination with 5-fluorouracil and leucovorin, lost
exclusivity in the U.S. in February 2008. It is also indicated for patients in whom metastatic colorectal cancer has recurred or
progressed following initial fluorouracil-based therapy. Camptosar is for intravenous use only. Camptosar worldwide revenues
decreased 42% to $563 million in 2008, compared to 2007.
•Xalatan, a prostaglandin, is the world’s leading branded agent to reduce elevated eye pressure in patients with open-angle glaucoma
or ocular hypertension. Xalatan's proven clinical benefits and studies demonstrating long-term safety should support the continued
growth of this important medicine. Xalacom, a fixed combination prostaglandin (Xalatan) and beta blocker (timolol), is available outside
the U.S. Xalatan/Xalacom worldwide revenues grew 9% in 2008, compared to 2007.
•Genotropin, the world’s leading human growth hormone, is used in children for the treatment of short stature with growth hormone
deficiency, Prader-Willi Syndrome, Turner Syndrome, Small for Gestational Age Syndrome, Idiopathic Short Stature (in the U.S. only)
and Chronic Renal Insufficiency (outside the U.S. only), as well as in adults with growth hormone deficiency. Genotropin worldwide
revenues grew 6% in 2008 to $898 million, compared to 2007, driven by its broad platform of innovative injection-delivery devices.
2008 Financial Report 23